Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

Summary

The goal of this clinical trial is to evaluate the safety and preliminary effectiveness of a new combination therapy in patients with advanced pancreatic cancer. The main questions it aims to answer are: 1. Is the combination of the peptide nanovaccine (ONVAX-01), an anti-PD-1 antibody, and chemotherapy safe and well-tolerated? 2. Does this combination treatment help shrink tumors or stop the progression of advanced pancreatic cancer? Participants will be asked to: 1. Receive doses of the peptide nanovaccine (ONVAX-01). 2. Receive intravenous infusions of an anti-PD-1 antibody and standard chemotherapy. 3. Undergo regular physical exams, blood tests, and imaging scans (such as CT or MRI) to monitor their health and the tumor's response to the treatment.

Timeline

Start

2026-06-20

Primary completion

2028-09-01

Completion

2029-09-01

Drugs

Indications